DDInter1124 DDInter1180
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Maprotiline {u} (Compound) resembles {v} (Compound) Protriptyline
Maprotiline {u} (Compound) resembles {v} (Compound) Demexiptiline
Maprotiline {u} (Compound) binds {v} (Gene) ABCB1
Maprotiline {u} (Compound) upregulates {v} (Gene) UBE2L6
Maprotiline {u} (Compound) palliates {v} (Disease) panic disorder
Maprotiline {u} (Compound) downregulates {v} (Gene) CCNA2
Maprotiline {u} (Compound) causes {v} (Side Effect) Angiopathy
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ephedrine
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Maprotiline (Compound) resembles Protriptyline (Compound)
Maprotiline (Compound) resembles Demexiptiline (Compound)
Maprotiline (Compound) binds ABCB1 (Gene)
Maprotiline (Compound) upregulates UBE2L6 (Gene)
Maprotiline (Compound) palliates panic disorder (Disease)
Maprotiline (Compound) downregulates CCNA2 (Gene)
Maprotiline (Compound) causes Angiopathy (Side Effect)
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib